Boston Children's and WuXi NextCODE are in a strategic partnership bringing together global leadership in pediatric medicine and sequence analysis. Claritas Genomics, affiliated with Boston Children's Hospital, is a CLIA-certified clinical laboratory serving the DNA-based diagnostic testing needs of children's hospitals that admit hundreds of thousands of patients with genetic disorders every year.
The partnership with Fudan-led Collaborative Innovation Center of Genetics and Development (CICGD) will empower CICGD scientists to perform gene sequencing and bioinformatics analysis with unparalleled speed and precision, thereby accelerating research, clinical diagnosis, and treatment of rare inherited diseases and malignant tumors.
Genomics England has selected WuXi NextCODE as the only Clinical Interpretation Partner working across the breadth of the 100,000 Genomes Project. WuXi NextCODE is the first to work with them on cancer samples and will also interpret samples in rare disease. Genomics England is working with WuXi NextCODE to drive up the quality of interpretation of genomic data. This will lead to better understanding of disease and more personalised care for patients in the future.